Skip to content
HelixEVOLabs home
Sign in
HelixEVO LabsRetatrutide40 mgLOT ________For research use only. Not for human or veterinary use.STORE 2–8 °CHelixEVO LabsRetatrutide40 mgLOT ________For research use only.Not for human or veterinary use.STORE 2–8 °C
Research peptide

Retatrutide

Retatrutide

Specification
Total quantity
40 mg
Pack
Sealed glass vial(s); vial count confirmed before release
Form
Lyophilised powder
Stated purity
Reported per lot on the certificate of analysis
Appearance
White to off-white lyophilised powder in a sealed glass vial under an aluminium crimp seal.
Storage
2–8 °C, sealed, protected from light
Shipping
Dispatched from the United Kingdom Monday to Wednesday only, under cold chain in insulated packaging with coolant, so that no consignment is held over a weekend in transit.
SKU
HX-RETA-40
AvailabilityOut of stock

Pricing releasing soon. Leave an email to be told once, or request a wholesale quote now.

Request a wholesale quote
For laboratory research use only. Not for human or veterinary consumption.

Analytical data

Latest released lotNo released lot yet

Analytical data appear here as soon as the first lot is released. Every released lot carries a certificate with HPLC purity and MS identity per compound.

Method

Purity by reversed-phase HPLC with UV detection; identity by electrospray mass spectrometry against the calculated monoisotopic or average mass. Endotoxin where stated. The certificate names the laboratory and the method for every result.

How to read a certificate →

Identity

Identity · Retatrutideverified 2026-09-22
In this product
40 mg
Synonyms
LY3437943, LY-3437943, retatrutidum, rétatrutide, retatrutida, Retatrutide [USAN], Retatrutide [WHO-DD]
CAS
2381089-83-2· FDA / NCATS GSRS, World Health Organization, NCBI PubChem
UNII
NOP2Y096GV· FDA / NCATS GSRS
PubChem CID
171390338
Formula
C221H342N46O68· World Health Organization, NCBI PubChem
Mol. weight
4731 g/mol· NCBI PubChem
Class
Synthetic 39-residue acylated peptide; glucagon, GIP and GLP-1 receptor triple agonist (incretin-class polyagonist)
Targets
Glucagon-like peptide-1 receptor (GLP-1R) - agonist, Gastric inhibitory polypeptide (glucose-dependent insulinotropic polypeptide) receptor (GIPR) - agonist, Glucagon receptor (GCGR) - agonist
Modifications
Positions 2 and 20 are 2-methylalanine (2-aminoisobutyric acid, Aib); position 13 is 2-methyl-L-leucine (alpha-methyl-leucine); the C-terminus (Ser39) is L-serinamide, i.e. C-terminally amidated; the epsilon-amino group of Lys17 is acylated with, reading outward, one 2-[2-(2-aminoethoxy)ethoxy]acetyl (AEEA) unit, an L-gamma-glutamyl spacer and a 19-carboxynonadecanoyl (C20 alpha,omega-fatty diacid) group. No disulfide bridge or glycosylation (GSRS glycosylation site count 0).
Sequence (one-letter) · 39 residues
  1. Y
  2. A
  3. Q
  4. G
  5. T
  6. F
  7. T
  8. S
  9. D
  10. Y
  11. S
  12. I
  13. L
  14. L
  15. D
  16. K
  17. K
  18. A
  19. Q
  20. A
  21. A
  22. F
  23. I
  24. E
  25. Y
  26. L
  27. L
  28. E
  29. G
  30. G
  31. P
  32. S
  33. S
  34. G
  35. A
  36. P
  37. P
  38. P
  39. S

Research overview

Retatrutide, developed under the code LY3437943, is a synthetic 39-residue acylated peptide characterised by the World Health Organization as an agonist of the glucagon, gastric inhibitory polypeptide and glucagon-like peptide 1 receptors 1. The FDA substance registry records the same three receptor relationships, each of agonist type 2. The sequence carries four modification types: 2-methylalanine at positions 2 and 20, 2-methyl-L-leucine at position 13, a C-terminal serinamide, and an acyl side chain on Lys17 built from an AEEA unit, a gamma-glutamyl spacer and a C20 fatty diacid 13. The molecular formula agreed by the WHO nomenclature entry and by PubChem for the parent peptide is C221H342N46O68, with a molecular weight of 4731 g/mol; the estimated formula published by the FDA substance registry describes the unmodified backbone and is not the formula of the acylated molecule 42. As research context, two randomised phase 2 trials and one randomised phase 3 trial have been published in peer-reviewed journals, while four further phase 3 trials have been announced by the developer without publication or posted registry results 567. No medicine containing retatrutide is authorised in the United Kingdom, the European Union or the United States 89. The monograph sets out the identity conflicts and the trial record in full.

  1. 1.WHO Drug Information Vol. 36, No. 4, 2022 - Proposed INN: List 128 (entry: retatrutidum / retatrutide). WHO Drug Information (2022). source
  2. 2.Retatrutide - Global Substance Registration System record, UNII NOP2Y096GV (version 24). FDA / NCATS GSRS (2026). source
  3. 3.ChEMBL molecule CHEMBL5095485 RETATRUTIDE (Protein, max phase 3). EMBL-EBI ChEMBL (2026). source
  4. 4.PubChem Compound CID 171390338 (retatrutide, parent peptide) - property and synonym records. NCBI PubChem (2026). source
  5. 5.Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine (2023). doi:10.1056/NEJMoa2301972
  6. 6.Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet (2023). doi:10.1016/S0140-6736(23)01053-X
  7. 7.Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B, Liu R, Chen Y, Patel H, Bartee A. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet (2026). doi:10.1016/S0140-6736(26)00967-0
  8. 8.MHRA Products database - search results for 'retatrutide'. Medicines and Healthcare products Regulatory Agency (2026). source
  9. 9.Drugs@FDA via openFDA API - query for generic name retatrutide (no matches). US Food and Drug Administration (openFDA) (2026). source
Retatrutide monograph

Regulatory status

Regulatory status · RetatrutideInvestigational or unlicensed compound

No medicine containing this compound is authorised in any jurisdiction checked. It has no established safety profile in humans outside registered clinical research. It is supplied for laboratory research only.

The rows below record the absence of authorisation and any compounding, evaluation or anti-doping status found on the date checked.

United Kingdom
No UK marketing authorisation: the MHRA products database returned 'There are no search results for retatrutide' on 2026-09-22, and the MHRA stated on 24 October 2025 that retatrutide 'has not been approved for UK use'.Checked 2026-09-22 · Medicines and Healthcare products Regulatory Agency
European Union
No EU marketing authorisation: the European Commission's Union Register of medicinal products for human use (page dated 21/09/2026) contains no entry for retatrutide.Checked 2026-09-22 · European Commission, DG SANTE
United States
Not FDA-approved and no application under review: Drugs@FDA (openFDA) has no match for retatrutide, FDA states (page updated 1 September 2026) that retatrutide is not a component of an FDA-approved drug and 'cannot be used in compounding under federal law', and Lilly plans to submit a BLA in Q1 2027.Checked 2026-09-22 · US Food and Drug Administration (openFDA)
WADA Prohibited List
Retatrutide is not named on the 2026 Prohibited List (in force 1 January 2026); as a substance with no approval by any governmental regulatory health authority it falls within class S0 'Non-approved substances', prohibited at all times.Checked 2026-09-22 · World Anti-Doping Agency
Handling and safety

Handle as a research chemical of unknown hazard in a laboratory setting with appropriate protective equipment. Keep sealed at 2–8 °C and protected from light. Safety data sheet: available on request until the SDS is published here.

Shipping

Dispatched in insulated cold-chain packaging with a coolant, Monday to Wednesday, to laboratory and business addresses within the United Kingdom. Destination rules are on the shipping policy.

Questions

Which retatrutide identity record does this material correspond to?
The parent peptide: CAS 2381089-83-2, UNII NOP2Y096GV, PubChem CID 171390338, molecular formula C221H342N46O68 [who-inn-pl128-2022][pubchem-cid-171390338]. The separate sodium record in the FDA substance registry (UNII LQ42M82ZU6) describes a salt and is not the identity recorded here [gsrs-retatrutide-sodium-lq42m82zu6].
Why do two different molecular weights appear in the literature?
Because two different structures are being weighed. About 4731 g/mol belongs to the acylated 39-residue peptide, while about 4092 Da is an estimated value published for the bare backbone without the two Aib residues, the alpha-methyl-leucine, the C-terminal amide or the fatty diacid [pubchem-cid-171390338][gsrs-retatrutide-nop2y096gv].
How is purity determined and what does the certificate of analysis show?
Chromatographic purity is determined by reversed-phase high-performance liquid chromatography with identity confirmed by mass spectrometry, and the lot certificate records the method, the chromatogram, the mass spectrum, net peptide content and the lot number. No pharmacopoeial monograph or official reference standard exists for retatrutide, so no compendial specification can be quoted [gsrs-retatrutide-nop2y096gv].
Are published solubility or solution-stability figures available?
No. No solubility, solid-state storage or solution-stability figure for retatrutide appears in any source on this site's allow-list, and the developer stated in July 2026 that its chemistry, manufacturing and controls data package was still being completed [lilly-triumph2-3-topline-2026]. Both fields are therefore recorded as null rather than filled from unsourced figures.
How is the material presented and stored before shipping?
As lyophilised powder in a sealed glass vial, held at 2 to 8 °C and protected from light until dispatch. The pack quantity is stated as total mass in the specification panel. Vials are sealed at fill and are not opened again before shipping.